ATW1H%ASUACAD.BITNET@oac.ucla.edu (Dr David Dodell) (08/28/89)
--- begin part 2 of 2 cut here ---
developing lung cancer, while women in the same category had seven times the
risk. Study participants included 332 lung cancer patients and 865 controls
from the island of Oahu. In order to ascertain the frequency and quantity of
vegetable consumption, researchers administered dietary questionnaires to all
subjects, and then classified the food groups on the basis of micronutrient
content. Among vitamin A components, only consumption of beta-carotene and the
other carotenoids with vitamin A activity was linked to cancer risk; beta-
carotene showed a protective role. Its protective mechanism was strongest for
male smokers, particularly for current and recent ex-smokers, whereas for
women, only ex-smokers and those who had never smoked showed this protective
effect. Of note, however, the researchers found that the reduction of lung
cancer risk is greater for overall vegetable consumption than with beta-
carotene intake per se. In addition, they reported that ``the study provides
indirect evidence for a protective effect against lung cancer from the
consumption of lycopene, lutein, and the cancer inhibitors particularly
abundant in cruciferous vegetables.'' JOURNAL OF THE NATIONAL OF THE NATIONAL
CANCER INSTITUTE August 2,1989;81:1158-64. (Compiled from Newspapers and
Medical Journals for IMTS's Healthweek In Review.)
Health InfoCom Network News Page 10
Volume 2, Number 31 August 28, 1989
===============================================================================
News from the National Institute of Dental Research
===============================================================================
Dental News from the
National Institute of Dental Research
07/13/89
CONSENSUS CONFERENCE URGES DENTAL TREATMENT FOR CANCER PATIENTS
Among the one million Americans who are diagnosed with cancer each year, some
400,000 will develop oral complications from their cancer treatments. These
painful and debilitating oral side effects, often severe enough to interfere
with a patient's trex8mnt and recovery, were the subject of a National
Institutes of Health Consensus Development Conference held April 17-19 on "The
Oral Complications of Cancer Therapies: Diagnosis, Prevention, and Treatment."
Copies of the Consensus Statement may be obtained by writing to the Public
Inquiries and Reports Section, Office of Planning, Evaluation, and
Communications, NIDR, NIH, Building 31, Room 2C35, 9000 Rockville Pike,
Bethesda, MD 20892. Proceedings from the conference will be published later
this year as a monograph of the Journal of the National Cancer Institute.
RESEARCHERS LINK HPV TO ORAL AND PHARYNGEAL CANCER
Using a sensitive genetic probe, University of North Carolina researchers
recently found DNA traces from several human papillomaviruses (HPVs)--common
causes of warts--in squamous cell carcinoma samples taken from patients with
oral and pharyngeal cancer. This finding suggests that HPV's may play a role
in the development of squamous cell carcinomas in this part of the body.
Health InfoCom Network News Page 11
Volume 2, Number 31 August 28, 1989
===============================================================================
Food & Drug Administration News
===============================================================================
Food Labelling Changes
P89-36 Food and Drug Administration
FOR IMMEDIATE RELEASE Jeff Nesbit - (301) 443-4177
July 28, l989 (Home) -- (703) 273-l043
HHS Secretary Louis W. Sullivan, M.D., today said that he has asked the
Food and Drug Administration to consider "sweeping changes" in the way foods
should be labeled.
In August, as part of the initiative, FDA Commissioner Frank E. Young,
M.D., Ph.D., will be publishing an advanced notice of proposed rule making
describing this effort in detail. The FDA will also hold a series of three or
four public hearings across the country beginning this fall to find out what
consumers want and need on food labels.
Under the guidelines set out by Dr. Sullivan, the FDA is expected to
propose a federal rule on the various aspects of food labeling early next
year.
The FDA has long required certain labeling -- such as ingredients and net
weight on packaged foods -- and has regulations for how nutritional
information should be displayed.
However, there is currently no comprehensive, mandatory food labeling
requirement for nutritional labeling for all foods, despite the federal
government's efforts to improve food labeling over the past two decades.
"Interest in food labeling has never been higher," said Dr. Sullivan.
"Food labeling bills have been introduced in Congress. Consumers are watching
what they eat more closely. Scientific knowledge about the effects of diet on
health has increased in recent years. And food manufacturers are providing
more information to consumers on their food labels."
Dr. Sullivan said the FDA will look at five major areas of food labeling
during the public hearings this fall and as the agency begins the process of
drafting the proposed federal rule, including:
* NUTRITION LABELING
Nutrition labeling is the voluntary listing of a food's nutritional
value, including vitamins and minerals, calories, sodium, fat, protein and
carbohydrates.
Since the current list of elements was developed, there have been
requests by both consumers and manufacturers to revise that list (e.g., to
eliminate some of the items such as certain detailed vitamin information, and
add others, such as cholesterol, fiber and saturated vs. unsaturated fat).
According to surveys, consumers say that labeling food for its
nutritional value is second in importance only to a listing of a food's
ingredients.
"For this reason, consumers might prefer to see the nutrition label
extended from its present 55 percent of packaged foods," said Dr. Young.
* LABEL FORMAT
Health InfoCom Network News Page 12
Volume 2, Number 31 August 28, 1989
Just as nutrition information is sought by consumers, there is an
increasing demand for more salient information in an easy-to-understand and
useful fashion.
Consumers want labels that help them to more readily identify foods as
low in fat and cholesterol, high in fiber and low in sodium. The FDA will
attempt to determine which label format is most helpful to consumers without
imposing significant new regulatory burdens on industry.
* INGREDIENT LABELING
FDA regulations currently require packaged food labels to list their
ingredients in descending order of predominance by weight (with bread, for
example, labeled as containing flour, eggs, sugar, yeast, preservatives and
artificial flavors and colors).
The FDA will examine a number of proposals, including those that major
ingredients should be listed by percentage, not just in order of weight; that
minor ingredients be exempted from the order of predominance labeling; and
that specific oil content be listed.
* DESCRIPTIONS OF FOOD
There are a number of ways in which the food label is used to describe
foods -- names established by standards of identity, common or usual names,
imitation of substitute foods, and descriptor labeling such as "low calorie,"
"low fat," "high fiber," "natural" and "organic." Other names for common foods
have been invented to make them sound more attractive (such as "snow cod" for
dogfish).
The FDA will examine whether the use of these terms is useful or
misleading, whether these terms in combination with other larger changes such
as revised ingredient and labeling are necessary, and whether some should be
standardized or prohibited, as well as whether some food standards should be
revised to provide for improved nutritional characteristics or replaced by a
simple, full listing of ingredients.
* HEALTH MESSAGES ON FOOD LABELS
In recent years, there has been increased use of food labels to impart
health messages to consumers on everything from fiber's protective benefits
against cancer and low cholesterol foods' effect on heart disease to high
calcium foods' impact on osteoporosis.
The FDA has traditionally determined that foods may not make such health-
related claims. However, scientific evidence has accumulated to support at
least some claims linking good diet to good health.
To date, the FDA has not reached a regulatory position allowing such
claims when they are appropriate while still protecting the public against
fraudulent or misleading claims. FDA plans to reach a position on health
messages on food labels with this initiative.
This initiative will involve close cooperation with the Institute of
Medicine which is under contract with the Public Health Service to review food
labeling issues. In recent years, the Surgeon General's Report on Nutrition
and Health and the National Academy of Science's Report on Diet and Health
provided the nation with authoritative views on the evidence linking diet and
nutrition to health.
"I believe all parties will welcome this initiative," said Dr. Young.
"Consumers want an opportunity to make the food label more useful. Health
Health InfoCom Network News Page 13
Volume 2, Number 31 August 28, 1989
professionals believe that better information about nutrition will have
benefits to health. And food manufacturers want to eliminate unnecessary food
labeling requirements, yet be permitted to make greater use of the food label
in conveying information about their products."
###
Tuesday July 26, 1989
Surfactant
P89-35 FOOD AND DRUG ADMINISTRATION
FOR IMMEDIATE RELEASE Eva Kemper -- (301) 443-3285
July 26, 1989 Home -- (301) 972-9273
The Food and Drug Administration today authorized wide use of an
experimental drug for the inside of the lungs to save thousands of premature
infants born with a breathing difficulty called Respiratory Distress Syndrome.
The syndrome is caused when the immature lungs of a premature infant are
not yet producing a naturally occurring surfactant -- a foamy substance that
coats the inside of the lungs and keeps them from collapsing when the infant
exhales.
FDA Commissioner Frank E. Young, M.D., Ph.D, announced that the FDA is
making the drug, a synthetic surfactant, available on a wide basis through
qualified hospitals to treat or prevent Respiratory Distress Syndrome. The
syndrome is also called hyaline membrane disease. In 1963, a baby boy born to
then-President and Mrs. John F. Kennedy died of the condition.
Although in the past two decades great strides have been made against the
syndrome, it remains a leading cause of death and disability among premature
infants. Among about 250,000 infants born prematurely each year in the United
States, up to 50,000 have the condition, which kills about 5,000.
FDA Commissioner Young said, "When there is adequate evidence that a drug
is effective and safe for a serious or life-threatening disease, and when no
satisfactory alternative exists, we can make the drug available under a
treatment IND -- before its approval for marketing -- with the cooperation of
the manufacturer. In this case, Burroughs Wellcome Co. agreed to make the
drug available early because of its potential benefit to thousands of infants
throughout the U.S. It is important to note that the evidence has come from
completed or partially completed controlled trials."
Under the "treatment IND" (or investigational new drug application), the
surfactant can be administered as a single dose immediately after birth to
help prevent death in high-risk middle-sized premature infants (700-1,100
grams, or 1.5 to 2.5 pounds) or as two doses, 12 hours apart, to treat middle
sized infants -- babies (700 - 1,350 grams, or 1.5 to 3 pounds) or large
babies (more than 1,350 grams, or 3 pounds) who have the syndrome.
The drug comes as a powder to be mixed with sterile water and then given
through a tube into the lungs. The premature infants must be on a mechanical
ventilator to receive the drug.
The drug has been associated with an increase in episodes of apnea
(temporary cessation of breathing).
Under the Treatment IND protocols, Burroughs Wellcome Co. will make
surfactant available to U.S. hospitals or institutions that can provide state-
of-the-art perinatal care to high-risk mothers and infants.
Burroughs Wellcome Co. of Research Triangle Park, N.C., will provide
surfactant under the trade name Exosurf Pediatric. Exosurf was invented by
Health InfoCom Network News Page 14
Volume 2, Number 31 August 28, 1989
Dr. John Clements of the University of California at San Francisco and
licensed to Burroughs Wellcome Co.
Physicians participating in the trials will receive the product at no
cost. Physicians who have questions about the Treatment IND protocols can
call Burroughs Wellcome Co. at 1-800-326-3282.
#####
Nutrex Aminex
P89-34 Food and Drug Administration
FOR IMMEDIATE RELEASE Bill Grigg - (301) 443-3285
July 21, 1989 (Home) -- (202) 652-1864
The Food and Drug Administration warned hospitals nationally today not to
use a nutritional powder called Nutrex Aminex made by the Nutrex Corporation
of Sunnyvale, Calif., because it contains a potentially fatal amount of
potassium.
The powder is blended with water and administered by mouth or by gastric
tube to patients unable to eat ordinary meals.
The problem was discovered after a patient at the Veterans Administration
Medical Center in Nashville, Tenn., developed heart arrhythmias and was
discovered to have high blood potassium. The patient recovered when the
administration of Aminex was withdrawn. Too much potassium can be fatal.
VA and FDA tests subsequently showed the Aminex diet powder used to make
the food was extremely high in the nutrient. FDA has not been successful in
obtaining a list of institutions to which the product was sold, and thus
issued a general press release in an attempt to get its warning to all
hospitals.
Packets of the powder, which are flavored strawberry, vanilla or orange
and are unflavored, are labeled, "Nutritionally complete elemental diet for
oral or tube feeding -- Nutrex Aminex Nutritional Powder."
####
Tuesday July 18, 1989
Aids treatment Registry
P89-33 Food and Drug Administration
FOR IMMEDIATE RELEASE Brad Stone - (301) 443-3285
July 18, 1989 (Home) -- (703) 440-6042
HHS Secretary Louis W. Sullivan, M.D., today announced the completion of
computerized listings through which AIDS patients and their doctors can get
up-to-date information on clinical trials of AIDS drugs and vaccines --
whether federally or privately sponsored -- and the general criteria for
participating in them.
"The AIDS Clinical Trial Information Service is on-line and ready to
provide the public with basic information concerning clinical trials,"
Secretary Sullivan said. "The data bank will provide the answers to important
basic questions and tell individuals where to get further details."
The listings were completed by a new data base developed by the Food and
Drug Administration on clinical trials sponsored by private companies and
Health InfoCom Network News Page 15
Volume 2, Number 31 August 28, 1989
organizations. This information complements that on federally sponsored
trials furnished by the National Institute of Allergy and Infectious Diseases.
Both are accessible via a Public Health Service toll-free hotline at 1-800
TRIALS-A. The Centers for Disease Control will administer the operation of
this hotline as part of its AIDS Information Clearinghouse.
The Public Health Service AIDS Clinical Trials Information Service was
designed to provide greater access to information about the trials underway to
test the efficacy of proposed treatments for AIDS and related conditions.
The Public Health Service AIDS Clinical Information Service was mandated
by the Health Omnibus Programs Extension Act passed by Congress in November
1988. The legislation also exempted basic information about clinical efficacy
trials for AIDS-related treatments from federal laws which had barred FDA from
disclosing any information on clinical trials without the sponsor's
permission.
FDA Commissioner Frank E. Young, M.D., Ph.D., said, "It is important that
people obtain early information on efficacy trials, which a change in the law
now permits us to provide. The information will enable people with AIDS to
identify clinical trials more quickly and efficiently, and participate in them
more widely."
The FDA data base, which began operation today, contains information on
every experimental AIDS and AIDS-related treatment undergoing clinical testing
for efficacy in FDA-sanctioned trials. The information will include the name
of the drug being tested, the indication for which the treatment is being
tested, eligibility criteria for patient enrollment and the location of the
clinical trial sites. In addition, FDA has requested each clinical trial
sponsor to allow the release of information beyond that required by the law,
including information about other experimental drugs that are in earlier, pre-
efficacy stages of testing.
FDA's recently established AIDS coordination staff developed this data
base, working with other parts of the agency and with the pharmaceutical
industry.
####
Health InfoCom Network News Page 16
Volume 2, Number 31 August 28, 1989
===============================================================================
Meeting Announcements
===============================================================================
SPECIAL ANNOUNCEMENT
--------------------
MEDINFO 89 SINGAPORE
6TH WORLD CONGRESS OF MEDICAL INFORMATICS
RAFFLES CITY CONVENTION CENTER
10-14 DECEMBER 1989
SINGAPORE
INFORMATICS IN SUPPORT OF GLOBAL HEALTH
----------------------------------------------------------------
MESSAGE FROM DR K C LUN
CHAIRMAN, SINGAPORE ORGANISING COMMITTEE
MEDINFO 89 SINGAPORE
DEAR FRIENDS OF IMIA,
DUE TO UNFORESEEN CIRCUMSTANCES, THE IMIA BOARD AND THE MEDINFO 89 STEERING
COMMITTEE HAD TO REVISE PLANS FOR MEDINFO 89, ORIGINALLY SCHEDULED TO BE HELD
IN BEIJING, PEOPLE'S REPUBLIC OF CHINA FROM 16-20 OCTOBER 1989. THERE WILL
NOW BE TWO MEDINFO 89: PART I IN BEIJING, AS SCHEDULED, AND PART II IN
SINGAPORE. MEDINFO 89 SINGAPORE WILL BE HELD IN SINGAPORE FROM 10-14 DECEMBER
1989. ENTRUSTED WITH THIS HEAVY RESPONSIBILITY OF ENSURING THE SUCCESS OF
THIS IMPORTANT INTERNATIONAL MEETING OF HEALTH INFORMATICIANS, THE SINGAPORE
ORGANISING COMMITTEE HAS BEEN WORKING VERY HARD TO PREPARE FOR THE EVENT. YOU
CAN CERTAINLY TELL BY THE SPEED IN WHICH WE HAD THE NEW DATES AND THE
CONVENTION FACILITIES FIXED UP AND THIS PRELIMINARY ANNOUNCEMENT REACHING OUT
TO YOU TO INFORM YOU OF THE CHANGE. I WISH TO GIVE YOU THE ASSURANCE THAT
THERE WILL BE NO LET UP IN THE ENTHUSIASM OF MY OC IN ENSURING THAT YOU WILL
HAVE A FIRST CLASS MEETING HERE IN DECEMBER IN A WORLD CLASS CONVENTION
CENTRE, THE RAFFLES CITY CONVENTION CENTRE THAT HAS PAR EXCELLENCE CONVENTION,
HOTEL AND SHOPPING FACILITIES. PLEASE NOTE THAT WE HAVE ALSO BEEN ABLE TO
NEGOTIATE FOR YOU VERY COMPETITIVE ROOM RATES FOR A COMFORTABLE STAY AT THE
WESTIN PLAZA AND WESTIN STAMFORD HOTELS, THE OFFICIAL CONVENTION HOTELS
LOCATED WITHIN THE RAFFLES CITY.
YOU WILL EXPERIENCE THE FULL SCIENTIFIC PROGRAM AT MEDINFO 89 SINGAPORE.
PAPERS TO BE PRESENTED WILL MAINTAIN THE HIGH SCIENTIFIC STANDARD THAT HAS
CHARACTERISED ALL PREVIOUS MEDINFOS. IN ADDITION TO THE SCIENTIFIC SESSIONS,
WE WILL MAINTAIN THE EXHIBITION, DEMONSTRATIONS, WORKSHOPS, "MEET THE EXPERT"
SESSIONS, VIDEO PRESENTATIONS, SOFTWARE EXCHANGE, AND POSTER SESSIONS. WE
HAVE ALSO PLANNED FOR YOU A RICH VARIETY OF SOCIAL PROGRAMS. FOR THOSE OF YOU
WHO ARE UNABLE TO TRAVEL TO CHINA, WE SHALL BE BRINGING A HISTORICAL PART OF
CHINA TO YOU AT MEDINFO 89 SINGAPORE. OUR CONGRESS OPENING RECEPTION WILL BE
A DINNER PARTY CUM EXHIBITION AT THE "EMPRESS", SINGAPORE'S LATEST MUSEUM THAT
HOUSES A MASSIVE EXHIBITION OF AUTHENTIC IMPERIAL TREASURES FROM THE QING
Health InfoCom Network News Page 17
Volume 2, Number 31 August 28, 1989
DYNASTY. THIS EXHIBITION IS MADE POSSIBLE THROUGH A HIGH LEVEL AGREEMENT
BETWEEN THE GOVERNMENTS OF THE PEOPLE'S REPUBLIC OF CHINA AND SINGAPORE. WE
HAVE ALSO ARRANGED POST-CONGRESS TOURS FOR YOU TO SPEND YOUR WINTER AT SOME OF
THE TOP TOURISM SPOTS IN THE TROPICAL FAR EAST. WE SHALL BE ANNOUNCING THE
DETAILS VERY SOON.
YOU HAVE UNDOUBTEDLY SEEN IN THE MEDIA OR HEARD FROM YOUR FRIENDS HOW
BEAUTIFUL AND CLEAN SINGAPORE IS AS AN ISLAND CITY AND HOW EFFICIENT AND
MODERNISED SINGAPORE IS AS A CONVENTION CITY. HERE'S YOUR CHANCE TO VISIT
SINGAPORE, THE TROPICAL GARDEN CITY. COME TO MEDINFO 89 SINGAPORE. WE LOOK
FORWARD TO BEING YOUR HOST.
CONGRESS VENUE
--------------
ALL SESSIONS WILL TAKE PLACE AT THE RAFFLES CITY CONVENTION CENTRE, LOCATED ON
LEVEL 4 OF THE WESTIN STAMFORD AND WESTIN PLAZA HOTELS. THE OPENING CEREMONY
WILL TAKE PLACE ON SUNDAY, 10 DECEMBER AND THE SCIENTIFIC SESSIONS WILL BE
HELD FROM 11 DECEMBER TO 14 DECEMBER 1989.
SCIENTIFIC PROGRAMME
--------------------
THE SCIENTIFIC PROGRAMME WILL CONSIST OF PLENARY SESSIONS, WITH INVITED
SPEAKERS AND SUBMITTED PAPERS. THERE WILL ALSO BE WORKSHOPS, FREE
COMMUNICATIONS, "MEET-THE-EXPERTS" SESSIONS, POSTER DISPLAYS AND SCIENTIFIC
DEMONSTRATIONS.
SCIENTIFIC TRADE EXHIBITION
---------------------------
IN ORDER TO GIVE CONGRESS PARTICIPANTS AN OPPORTUNITY TO ACQUAINT THEMSELVES
WITH THE LATEST DEVELOPMENTS IN HEALTH INFORMATICS HARDWARE AND SOFTWARE, A
TRADE EXHIBITION WILL BE HELD WITHIN THE CONGRESS VENUE. COMPANIES INTERESTED
IN PARTICIPATING IN THE TRADE EXHIBITION ARE ADVISED TO CONTACT THE ORGANISING
COMMITTEE AS SOON AS POSSIBLE.
SOCIAL PROGRAMME
----------------
AN ATTRACTIVE SOCIAL PROGRAMME WILL BE ARRANGED FOR PARTICIPANTS AND
ACCOMPANYING PERSONS. THE MAIN ATTRACTION WILL BE A DINNER PARTY CUM
EXHIBITION AT THE "EMPRESS" WHICH HOUSES A VAST COLLECTION OF AUTHENTIC
IMPERIAL TREASURES FROM THE QING DYNASTY IN CHINA.
OFFICIAL LANGUAGE
-----------------
THE OFFICIAL LANGUAGE OF MEDINFO 89 SINGAPORE WILL BE ENGLISH.
Health InfoCom Network News Page 18
Volume 2, Number 31 August 28, 1989
OFFICIAL TRAVEL AGENT
---------------------
WORLD EXPRESS HAS BEEN APPOINTED AS THE OFFICIAL TRAVEL AGENT. THIS
ORGANISATION, WITH ITS WORLDWIDE NETWORK OF OFFICES, WILL ASSIST IN ALL TRAVEL
AND HOTEL ARRANGEMENTS. THEIR ADDRESS IS:
WORLD EXPRESS PTE LTD
114 MIDDLE ROAD #05-01
SINGAPORE 0718
TEL: (65)-336-3877
TLX: (65)-33372
FAX: (65)-339-8625
ATTN: MEDINFO 89 SINGAPORE
REGISTRATION
------------
REGISTRATION FEES (US$) ARE AS FOLLOWS:
BEFORE OCT 1 ON/AFTER OCT 1
ACTIVE PARTICIPANTS US$320 US$360
STUDENT PARTICIPANTS US$100 US$120
ACCOMPANYING PERSONS US$115 US$129
EXHIBITION PARTICIPANTS US$ 50 US$ 50
TRAVEL AND VISAS
----------------
A VALID INTERNATIONAL PASSPORT IS NECESSARY. FREE 14-DAY ENTRY VISA WILL BE
GRANTED UPON ARRIVAL AT CHANGI INTERNATIONAL AIRPORT FOR SOCIAL VISITS TO ALL
EXCEPT NATIONALS OF THE FOLLOWING COUNTRIES: AFGHANISTAN, CAMBODIA, LAOS,
PEOPLE'S REPUBLIC OF CHINA, SOVIET UNION AND VIETNAM. FOR THESE NATIONALS,
VISA APPLICATIONS SHOULD BE MADE IN ADVANCE FROM THE NEAREST SINGAPORE
DIPLOMATIC MISSION.
PARTICIPANTS TRAVELLING ON A HONG KONG DOCUMENT OF IDENTITY OR A HOLDER OF A
REFUGEE TRAVEL DOCUMENT ISSUED BY THE ARAB COUNTRIES WILL ALSO REQUIRE ADVANCE
VISA APPLICATION.
PARTICIPANTS ARE NEVERTHELESS ADVISED TO CHECK WITH THEIR MINISTRY OF FOREIGN
AFFAIRS OR THE NEAREST SINGAPORE DIPLOMATIC MISSION.
INTERNATIONAL HEALTH CERTIFICATES ARE REQUIRED FOR ARRIVALS FROM YELLOW FEVER
ENDEMIC/INFECTED AREAS.
HOTEL RESERVATION
-----------------
THE OFFICIAL CONGRESS HOTELS ARE THE WESTIN PLAZA AND THE WESTIN STAMFORD.
Health InfoCom Network News Page 19
Volume 2, Number 31 August 28, 1989
THE OC HAS RESERVED ROOMS AT SPECIAL CONGRESS ROOM RATES OF US$80++ FOR THE
PLAZA AND US$70++ FOR THE STAMFORD. ROOMS WILL BE AVAILABLE ON A FIRST-COME-
FIRST-SERVED BASIS. A ONE-NIGHT ROOM DEPOSIT IS NECESSARY TO CONFIRM HOTEL
BOOKING. TO ENJOY THESE CONCESSION RATES, HOTEL BOOKINGS MUST BE MADE EITHER
THROUGH THE OC SECRETARIAT OR THE OFFICIAL TRAVEL AGENT, WORLD EXPRESS PTE
LTD. NOTE: A ONE-NIGHT ROOM DEPOSIT PAYABLE TO "MEDINFO 89 SINGAPORE" IS
REQUIRED TO CONFIRM HOTEL RESERVATION.
( ++ REFERS TO 10% SERVICE CHARGE AND 3% GOVT.TAX)
THE UNIT OF CURRENCY FOR SINGAPORE IS THE SINGAPORE DOLLAR.
(US$1.00 = APPROX S$2.00)
FOR FURTHER INFORMATION CONCERNING REGISTRATION, HOTEL
RESERVATIONS, EXHIBITIONS, PLEASE CONTACT:
THE SECRETARIAT
MEDINFO 89 SINGAPORE
C/O DEPT OF COMMUNITY, OCCUPATIONAL
AND FAMILY MEDICINE
NATIONAL UNIVERSITY HOSPITAL
LOWER KENT RIDGE ROAD
SINGAPORE 0511
TEL: (65)-772-4299
FAX: (65)-772-4252
BITNET: LUNKC @ NUSVM
TELEX: UNISPO RS33943
TELEGRAM: UNIVSPORE
*********************************************************************
*********************************************************************
* *
* THIS SPECIAL ANNOUNCEMENT HAS BEEN ISSUED FOR THE INFORMATION *
* OF THE MANY PEOPLE WHO HAVE ENQUIRED ABOUT "MEDINFO 89 SINGAPORE" *
* IT PRECEDES A COLOURFUL "SPECIAL ANNOUNCEMENT" FLYER WHICH IS *
* CURRENTLY BEING PRINTED AND WILL BE DISTRIBUTED SHORTLY. *
* *
*********************************************************************
*********************************************************************
Health InfoCom Network News Page 20
--- end part 2 of 2 cut here ---